{"id":35983,"date":"2015-05-12T07:23:47","date_gmt":"2015-05-12T11:23:47","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35983"},"modified":"2015-05-12T07:23:47","modified_gmt":"2015-05-12T11:23:47","slug":"amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983","title":{"rendered":"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Amgen, Inc. (NASDAQ:AMGN)<\/strong> has partnered up with Fidelity Biosciences to venture into the gene editing research field.<\/p>\n<p style=\"text-align: justify;\">The scientific community has recently shed more light on gene editing, citing the need for more focus on the subject. More finances have been allocated to the research, thus evidence of the rapidly growing appeal of the subject.<\/p>\n<p style=\"text-align: justify;\">Amgen will power up together with Fidelity to join a spinoff that is focused on uncovering the hidden potential that lays within gene editing. The new venture will bring in a new competition to the rapidly growing semi-industry, being a more specialized division of a wider gene research field. The two companies will join the already existing company in the gene editing field called Precision Biosciences which originated from Duke.<\/p>\n<p style=\"text-align: justify;\">Precision Biosciences has been in the limelight for a while. venBio is one of the initial companies to join the movement before Fidelity and Amgen joined the cause. The spinoff continues to capture the attention of investors because of the promising nature of the research. The venture has thus benefited from a large pool of funds. These funds have been allocated towards the development of a gene editing platform called ARCUS.<\/p>\n<p style=\"text-align: justify;\">The platform will bring together the benefits accrued from TALEN and CRISPR especially with the benefits that will be expected from the knowledge derived from endo nucleases. The acquisition of the funding was greatly influenced by the company\u2019s CEO, Matthew Cane. He also revealed a bit more about ARCUS as a synthetic nuclease those scientists at Precision Biosciences. It has been instrumental in solving many of the problems faced in the initial stages.<\/p>\n<p style=\"text-align: justify;\">To increase the firm&#8217;s productivity, Cane plans on increasing the staff that at the moment consists of 18 individuals. The projected staff number ranges from 35 to 45. A proportion of the pool of funds collected from investors will be paid as salaries to the new staff. With more hands on deck, Cane and his team will be in a position to optimize on their research and enhance the possibilities for a breakthrough.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen, Inc. (NASDAQ:AMGN) has partnered up with Fidelity Biosciences to venture into the gene editing research field. The scientific community has recently shed more light [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":28307,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2831,11466,1520],"stock_ticker":[],"class_list":["post-35983","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-amgen-inc-nasdaqamgn","tag-matthew-cane","tag-nasdaqamgn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Amgen, Inc. (NASDAQ:AMGN) has partnered up with Fidelity Biosciences to venture into the gene editing research field. The scientific community has recently shed more light [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-12T11:23:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"275\" \/>\n\t<meta property=\"og:image:height\" content=\"183\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round\",\"datePublished\":\"2015-05-12T11:23:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983\"},\"wordCount\":358,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg\",\"keywords\":[\"Amgen Inc. (NASDAQ:AMGN)\",\"Matthew Cane\",\"NASDAQ:AMGN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983\",\"name\":\"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg\",\"datePublished\":\"2015-05-12T11:23:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg\",\"width\":275,\"height\":183},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983","og_locale":"en_US","og_type":"article","og_title":"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round - Wall Street PR","og_description":"Amgen, Inc. (NASDAQ:AMGN) has partnered up with Fidelity Biosciences to venture into the gene editing research field. The scientific community has recently shed more light [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-12T11:23:47+00:00","og_image":[{"width":275,"height":183,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round","datePublished":"2015-05-12T11:23:47+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983"},"wordCount":358,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg","keywords":["Amgen Inc. (NASDAQ:AMGN)","Matthew Cane","NASDAQ:AMGN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983","url":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983","name":"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg","datePublished":"2015-05-12T11:23:47+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Amgen-Inc..jpg","width":275,"height":183},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/amgen-inc-nasdaqamgn-and-fidelity-biosciences-help-bankroll-another-upstart-gene-editing-player-with-25-6m-a-round-35983#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Amgen, Inc. (NASDAQ:AMGN) And Fidelity Biosciences Help Bankroll Another Upstart Gene-Editing Player With $25.6m A Round"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35983"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35983\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/28307"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35983"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}